Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.51)
# 274
Out of 5,138 analysts
67
Total ratings
61.7%
Success rate
20.5%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $17.52 | +14.16% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $79.98 | -4.98% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $12.16 | +15.13% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $141.65 | -29.40% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $26.78 | +15.76% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $20.52 | -56.14% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $41.41 | -20.31% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $162.02 | +17.27% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $112.50 | -11.11% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $25.24 | -24.72% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $387.37 | +0.68% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $70.33 | -21.80% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $112.14 | -50.95% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $139.64 | +14.58% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $618.72 | +8.29% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.92 | +237.84% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,460.63 | -4.15% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.21 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $48.39 | +85.99% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $235.99 | +14.41% | 4 | Dec 20, 2023 |
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $17.52
Upside: +14.16%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $79.98
Upside: -4.98%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $12.16
Upside: +15.13%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $141.65
Upside: -29.40%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $26.78
Upside: +15.76%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $20.52
Upside: -56.14%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $41.41
Upside: -20.31%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $162.02
Upside: +17.27%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $112.50
Upside: -11.11%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $25.24
Upside: -24.72%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $387.37
Upside: +0.68%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $70.33
Upside: -21.80%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $112.14
Upside: -50.95%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $139.64
Upside: +14.58%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $618.72
Upside: +8.29%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.92
Upside: +237.84%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,460.63
Upside: -4.15%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.21
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $48.39
Upside: +85.99%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $235.99
Upside: +14.41%